[{"orgOrder":0,"company":"Invex Therapeutics","sponsor":"Premier Research Group | University Hospital Birmingham | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Invex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa","highestDevelopmentStatusID":"10","companyTruncated":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa"}]
Find Clinical Drug Pipeline Developments & Deals by Invex Therapeutics
Reset All
